Citations

Showing 10 of 107969 citations.

SCAI/ACC/AHA Expert Consensus Document: 2014 Update on Percutaneous Coronary Intervention Without On-Site Surgical Backup
Dehmer, Gregory , Blankenship, James C. , Dwyer, James G., Feldman, Dmitriy N. , Gardner, Timothy J., Çilingiroğlu, Mehmet , Grines, Cindy L. , Singh, Mandeep

Mayo Clinic

Circulation | March 18, 2014 | Volume: 129 | Issue: 24 | Pages: 2610-2626

10.1161/cir.0000000000000037 | PMID 24637561 Get It

American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes
Ellis, Lee M. , Voest, Emile E. , Cortazar, Patricia , Lilenbaum, Rogério, Sima, Camelia S., Gönen, Mithat , Schilsky, Richard L. , Meropol, Neal J. , Schnipper, Lowell E., Bernstein, David S. , Berlin, Jordan D. , Sargent, Daniel J. , Garrett‐Mayer, Elizabeth , Herbst, Roy S. , Venook, Alan P.

Mayo Clinic

Journal of Clinical Oncology | March 18, 2014 | Volume: 32 | Issue: 12 | Pages: 1277-1280

10.1200/jco.2013.53.8009 | PMID 24638016 Get It

Pathologic and Molecular Features Correlate With Long-Term Outcome After Adjuvant Therapy of Resected Primary GI Stromal Tumor: The ACOSOG Z9001 Trial
Corless, Christopher L. , Kolesnikova, Violetta, Maki, Robert G. , Pisters, Peter W. T., Blackstein, Martin E., Blanke, Charles D. , Heinrich, Michael C. , Patel, Shreyaskumar , McCarter, Martin D. , Owzar, Kouros , DeMatteo, Ronald P. , Antonescu, Cristina R. , Demetri, George D., von Mehren, Margaret, Ballman, Karla V. , Demetri, George D. , Mehren, Margaret von , Maki, Robert G , Heinrich, Michael C

Mayo Clinic

Journal of Clinical Oncology | March 18, 2014 | Volume: 32 | Issue: 15 | Pages: 1563-1570

10.1200/jco.2013.51.2046 | PMID 24638003 Get It

Purpose The ACOSOG (American College of Surgeons Oncology Group) Z9001 (Alliance) study, a randomized, placebo-controlled trial, demonstrated that 1 year of adjuvant imatinib prolonged recurrence-free survival (RFS) after resection of primary GI stromal tumor (GIST). We sought to determine the pathologic and molecular factors associated with patient outcome. Patients and Methods There were 328 patients assigned to the placebo arm and 317 to the imatinib arm. Median patient follow-up was 74 months. There were 645 tumor specimens available for mitotic rate or mutation analysis. Results RFS remained superior in the imatinib arm (hazard ratio, 0.6; 95% CI, 0.43 to 0.75; Cox model–adjusted P < .001). On multivariable analysis of patients in the placebo arm, large tumor size, small bowel location, and high mitotic rate were associated with lower RFS, whereas tumor genotype was not significantly associated with RFS. Multivariable analysis of patients in the imatinib arm yielded similar findings. When comparing the two arms, imatinib therapy was associated with higher RFS in patients with a KIT exon 11 deletion of any type, but not a KIT exon 11 insertion or point mutation, KIT exon 9 mutation, PDGFRA mutation, or wild-type tumor, although some of these patient groups were small. Adjuvant imatinib did not seem to alter overall survival. Conclusion Our findings show that tumor size, location, and mitotic rate, but not tumor genotype, are associated with the natural history of GIST. Patients with KIT exon 11 deletions assigned to 1 year of adjuvant imatinib had a longer RFS.
Upper Extremity Orthoses Use in Amyotrophic Lateral Sclerosis/Motor Neuron Disease: Three Case Reports
Ivy, Cindy, Materi, Miranda M., Ivy, Cindy C, Smith, Susan M, Smith, Susan M.

Mayo Clinic

HAND | March 18, 2014 | Volume: 9 | Issue: 4 | Pages: 543-550

10.1007/s11552-014-9626-x | PMID 25414620 Get It

Background Central to the armamentarium of a hand therapist is evaluation for successful orthotic use. Orthoses can have a profound effect on quality of life in persons with amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). The purposes of orthoses are to decrease the effects of muscle imbalance, provide assistance in performance of activities of daily living (ADLs), prevent joint contracture, and relieve pain. There are few published accounts on the usefulness of orthoses and ALS. The purpose of this paper is to expand the body of literature by describing three successful cases. Methods Three cases illustrate effects on weakened proximal muscles, wrist extensors, thenar musculature, and intrinsic muscles. The primary outcome measure is patient report, but functional rating scales, goniometry, quality of life scores, and pinch strength when obtainable are described. Results Due to the progressive nature of the disease, outcome measures can be inconclusive. Patient report of increased life satisfaction and ability to participate in daily life is the critical outcome in these case examples. In all cases, satisfaction increased. Some of the stated changes include the following: ability to manipulate objects, grip, eat, wipe face, hold phone, use iPad®, and adjust hat. Conclusions Upper extremity orthotic use can be a beneficial adjunct contributing to the quality of life for individuals with ALS/MND. We have observed positive responses in pain control, contracture management, functional positioning, and increased independence with the use of orthoses. Designing appropriate means of studying effects of orthosis intervention is deficient in the current scientific literature.
Endoplasmic Reticulum Stress-Activated Transcription Factor ATF6α Requires the Disulfide Isomerase PDIA5 To Modulate Chemoresistance
Higa, Arisa, Taouji, Saı̈d , Lhomond, Stéphanie , Jensen, Devon, Fernández-Zapico, Martín E. , Simpson, Jeremy C. , Pasquet, Jean‐Max , Chevet, Éric , Schekman, Randy W. , Chevet, Eric

Mayo Clinic

Molecular and Cellular Biology | March 18, 2014 | Volume: 34 | Issue: 10 | Pages: 1839-1849

10.1128/mcb.01484-13 | PMID 24636989 Get It

Review: In relapsing–remitting multiple sclerosis, disease-modifying agents reduce annual relapse rates
Weinshenker, Brian G. , Weinshenker, Brian G

Mayo Clinic

Annals of Internal Medicine | March 17, 2014 | Volume: 160 | Issue: 6 | Pages: JC5

10.7326/0003-4819-160-6-201403180-02005 | PMID 24638183 Get It

A Prospective Study of Chronic Obstructive Pulmonary Disease and the Risk for Mild Cognitive Impairment
Singh, Balwinder , Mielke, Michelle M. , Parsaik, Ajay K. , Cha, Ruth H., Roberts, Rosebud O., Scanlon, Paul D., Geda, Yonas E. , Christianson, Teresa J., Petersen, Ronald C. , Cha, Ruth H., Pankratz, V. Shane , Mielke, Michelle M , Singh, Balwinder , Geda, Yonas E

Mayo Clinic

JAMA Neurology | March 17, 2014 | Volume: 71 | Issue: 5 | Pages: 581

10.1001/jamaneurol.2014.94 | PMID 24637951 Get It

Dermatology Residency Selection Criteria with an Emphasis on Program Characteristics: A National Program Director Survey
Alikhan, Ali , Rezaei, Arash, Fazel, Nasim , Gorouhi, Farzam

Mayo Clinic

Dermatology Research and Practice | March 17, 2014 | Volume: 2014 | Issue: No issue available | Pages: 1-8

10.1155/2014/692760 | PMID 24772165 Get It

Background. Dermatology residency programs are relatively diverse in their resident selection process. The authors investigated the importance of 25 dermatology residency selection criteria focusing on differences in program directors’ (PDs’) perception based on specific program demographics.Methods. This cross-sectional nationwide observational survey utilized a 41-item questionnaire that was developed by literature search, brainstorming sessions, and online expert reviews. The data were analyzed utilizing the reliability test, two-step clustering, andK-means methods as well as other methods. The main purpose of this study was to investigate the differences in PDs’ perception regarding the importance of the selection criteria based on program demographics.Results. Ninety-five out of 114 PDs (83.3%) responded to the survey. The top five criteria for dermatology residency selection were interview, letters of recommendation, United States Medical Licensing Examination Step I scores, medical school transcripts, and clinical rotations. The following criteria were preferentially ranked based on different program characteristics: “advanced degrees,” “interest in academics,” “reputation of undergraduate and medical school,” “prior unsuccessful attempts to match,” and “number of publications.”Conclusions. Our survey provides up-to-date factual data on dermatology PDs’ perception in this regard. Dermatology residency programs may find the reported data useful in further optimizing their residency selection process.
Digital imaging analysis to assess scar phenotype
Smith, Brian J., Nidey, Nichole , Miller, Steven F. , Uribe, Lina M. Moreno , Baum, Christian L. , Wehby, George L. , Smith, Brian J., Hamilton, Grant , Dunnwald, Martine

Mayo Clinic

Wound Repair and Regeneration | March 17, 2014 | Volume: 22 | Issue: 2 | Pages: 228-238

10.1111/wrr.12141 | PMID 24635173 Get It

AbstractIn order to understand the link between the genetic background of patients and wound clinical outcomes, it is critical to have a reliable method to assess the phenotypic characteristics of healed wounds. In this study, we present a novel imaging method that provides reproducible, sensitive, and unbiased assessments of postsurgical scarring. We used this approach to investigate the possibility that genetic variants in orofacial clefting genes are associated with suboptimal healing. Red‐green‐blue digital images of postsurgical scars of 68 patients, following unilateral cleft lip repair, were captured using the 3dMD imaging system. Morphometric and colorimetric data of repaired regions of the philtrum and upper lip were acquired using ImageJ software, and the unaffected contralateral regions were used as patient‐specific controls. Repeatability of the method was high with intraclass correlation coefficient score > 0.8. This method detected a very significant difference in all three colors, and for all patients, between the scarred and the contralateral unaffected philtrum (p ranging from 1.20−05 to 1.95−14). Physicians’ clinical outcome ratings from the same images showed high interobserver variability (overall Pearson coefficient = 0.49) as well as low correlation with digital image analysis results. Finally, we identified genetic variants in TGFB3 and ARHGAP29 associated with suboptimal healing outcome.